ClinicalTrials.gg
TerminatedNCT04001036Updated Mar 3, 2023

Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD

A Phase 2 interventional study of 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine and 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine in End Stage Renal Disease, sponsored by Iperboreal Pharma Srl. Terminated at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-03.

Sponsored by Iperboreal Pharma Srl · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
prematurely interrupted due to significant difficulties in the completion of the sample size defined by the study protocol

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Kidney Failure, Chronic with a site in Italy — 14 open to participants now, 19 under way, 4 of them phase 3. Kidney Failure, Chronic · Italy.

Enrollment
53rd of 59
11 · median 80
Started
2019
the only one that year
Phase 2
11 of 75
2 open now
Registered
49th of 75
by date
Lead sponsor
6 of 75
Iperboreal Pharma Srl

Among the 75 studies in Kidney Failure, Chronic with a site in Italy, this one is the 53rd largest by enrollment of the 59 interventional ones that give a count, is the only one that started in 2019, is one of 11 in phase 2, and was the 49th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

14 of the 75 studies in Kidney Failure, Chronic with a site in Italy are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Kidney Failure, Chronic with a site in Italy, or all of them as a file.
02

Study summary

Prospective, randomized, controlled clinical trial. The aim is to compare the effects of the peritoneal dialysis solution IPX15, containing glucose (0.5%), xylitol (1.5%) and L-carnitine (0.02%) as osmotic agents (comparable to the standard 2.5% glucose PD solution), for the nocturnal exchange with the PD solution IPX07, containing glucose (0.5%), xylitol (0.7%) and L-carnitine (0.02%) as osmotic agents (comparable to the standard 1.5% glucose PD solution), for the diurnal (short dwell) exchanges. Planned total recruitment is 40 patients with stable end-stage renal disease (ESRD) treated by continuous ambulatory peritoneal dialysis (CAPD). Treatment duration will be 4 weeks plus a 4 weeks safety follow up with no treatment.

03

Conditions studied

  • End Stage Renal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ESRD treated for at least three months with CAPD, as stated by the medical staff of the center;
  • Stable clinical condition within four weeks before the screening period, certified by medical/surgical history, physical examination and laboratory exploration;
  • level ≥ 9g/dL;
  • Absence of acute peritonitis and/or peritoneal catheter infection (either exit site or subcutaneous tunnel) episodes within three months before selection;
  • To understand and sign an form.

Exclusion criteria

Exclusion Criteria:

  • History of alcohol or drug abuse in the last six months before selection for the study;
  • Androgen therapy in the last six months before selection;
  • Active infections;
  • History of congestive heart failure stage III and IV (NYHA);
  • History of major cardiovascular events like stroke, acute myocardial infarction, coronary or other arterial revascularization procedures in the last three months before selection;
  • cardiac arrhythmia;
  • Clinically relevant abnormalities of functional hepatic tests;
  • Therapy with L-carnitine or its derivatives in the last three months before selection;
  • Pregnancy, lactating women or female subjects of who do not use an effective method of ;
  • Presence of relevant chronic medical conditions that could suggest exclusion of patient from the study or could interfere with the assessment of study parameters, especially if the is less then one year;
  • Participation in another clinical study within the past month;
  • Known allergic reactions to L-carnitine or xylitol.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Experimental peritoneal dialysis solution IPX15

    Patients will receive treatment with the experimental solution for nocturnal (long-dwell) exchange. For daily (short-dwell) exchanges, all patients will continue the 1 to 3 bags of glucose peritoneal dialysis solution as for their pre-randomization prescription.

    Drug: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine

  • Experimental
    Experimental peritoneal dialysis solution IPX07

    Patients will receive 1 to 3 daily (short-dwell) exchanges with the experimental solution (the number of exchanges will be based on their pre-randomization prescription). All patients will receive icodextrin for nocturnal (long-dwell) exchange.

    Drug: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine

Interventions

  • Drug1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine

    Drug page: XylitolStudies of XylitolXylitol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One bag for nocturnal (long-dwell) exchange.

    Also known as: IPX15

  • Drug0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine

    Drug page: XylitolStudies of XylitolXylitol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One to three, daily (short-dwell) exchanges

    Also known as: IPX07

06

What researchers measure

Primary outcomes

  1. Daily ultrafiltration volume

    Change from baseline

    Time frame: 28 days

Secondary outcomes

  1. Peritoneal equilibration test

    Change from baseline

    Time frame: 28 days

  2. Weekly total urea Kt/V

    Change from baseline

    Time frame: 28 days

  3. Weekly total creatinine clearance

    Change from baseline

    Time frame: 28 days

  4. Adverse Events

    Information about all adverse events, whether volunteered by the patient, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, will be collected, recorded and followed as appropriate.

    Time frame: 2 months

07

Study locations

1 site
  • Department of Nephrology, University of Chieti
    Chieti, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Aug 2022, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2019
First posted
Jun 27, 2019
StartActual
Sep 1, 2019
Primary completionActual
Aug 30, 2022
CompletionActual
Aug 30, 2022
Last update
Mar 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04001036
Lead sponsor
Iperboreal Pharma Srl
Responsible party
Sponsor
First posted
Jun 27, 2019
Start date
Sep 1, 2019
Primary completion
Aug 30, 2022
Completion
Aug 30, 2022
Last update
Mar 3, 2023

Study contacts

Mario Bonomini, MD
principal investigator · Institute of Nephrology, G. D'annunzio University, Chieti, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xylitol

Start the discussion